LOGIN  |  REGISTER
Recursion

Zynex Recognized in Top 25 Medical Device Companies for 2024

February 02, 2024 | Last Trade: US$2.25 0.05 -2.17

ENGLEWOOD, Colo., Feb. 2, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report recognized Zynex as 9th amongst the Top 25 Medical Device Companies for 2024.

"We're pleased to be included in the Top 25 Medical Device Companies for 2024," said Thomas Sandgaard, CEO of Zynex. "The Healthcare Technology Report's rankings include some of the largest and most innovative companies in the medical device space. We are proud to be included amongst our distinguished peers and believe these rankings are indicative of our outsized influence within the field. We look forward to the coming year as we continue to build on a successful 2023."

About The Healthcare Technology Report  

The Healthcare Technology Report (HLTR) provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector. 

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594

C4 Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page